• / Free eNewsletters & Magazine
  • / My Account
Home>Drug Companies

Drug Companies

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  6. Research
  1. Infiniti Research Identifies New Market Opportunities for Rheumatology Centers Across North America and Europe in Latest Study

    Infiniti Research Identifies New Market Opportunities for Rheumatology Centers Across North America and Europe in Latest Study

  2. FDA Grants Priority Review for Eagle Pharmaceuticals ’ Ryanodex NDA for the Treatment of Exertional Heat Stroke

    FDA Grants Priority Review for Eagle Pharmaceuticals ’ Ryanodex NDA for the Treatment of Exertional Heat Stroke

  3. eClinicalHealth Celebrates 5 Years in Business Supporting Direct-to-Patient Research Models for Clinical Trials

    eClinicalHealth Celebrates 5 Years in Business Supporting Direct-to-Patient Research Models for Clinical Trials

  4. Liquid Biopsy Market - Trends and Forecasts by Technavio

    Liquid Biopsy Market - Trends and Forecasts by Technavio

  5. UPDATE: Pulitzer Prize winner on 'Sweat,' her Broadway play about Trump's America: 'Being poor is one of the hardest jobs in the world'

    UPDATE: Pulitzer Prize winner on 'Sweat,' her Broadway play about Trump's America: 'Being poor is one of the hardest jobs in the world'

  6. Keller Rohrback L.L.P. Files Class-Action Lawsuit Over the Inflated Price of Insulin

    Keller Rohrback L.L.P. Files Class-Action Lawsuit Over the Inflated Price of Insulin

  7. Pulmonary Arterial Hypertension (PAH) Therapeutics - Global Strategic Business Report 2017: Focus on Endothelin Receptor Antagonist, Prostacyclin and Prostacyclin, PDE-5 Inhibitors & sGC Stimulator - ...

    Pulmonary Arterial Hypertension (PAH) Therapeutics - Global Strategic Business Report 2017: Focus on Endothelin Receptor Antagonist, Prostacyclin and Prostacyclin, PDE-5 Inhibitors & sGC Stimulator - Research and Markets

  8. UPDATE: Bernie Sanders thinks this $89,000-a-year drug should be $1,000 a year

    UPDATE: Bernie Sanders thinks this $89,000-a-year drug should be $1,000 a year

  9. Global Lifestyle Drugs Market to Grow at a CAGR of 2.8% by 2017-2021, with Allergan, BMS, Eli Lilly & Pfizer Leading the Way - Research and Markets

    Global Lifestyle Drugs Market to Grow at a CAGR of 2.8% by 2017-2021, with Allergan, BMS, Eli Lilly & Pfizer Leading the Way - Research and Markets

  10. SpendEdge to Host a Webinar on the Benchmarking of Integrated Facilities Management Best Practices

    SpendEdge to Host a Webinar on the Benchmarking of Integrated Facilities Management Best Practices

12345

©2017 Morningstar Advisor. All right reserved.